Studies related to HDL-C and Vitamin E

Pioglitazone, Vitamin E, Or Placebo For Nonalcoholic Steatohepatitis

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 222
Gender Both Genders
Age Range 30-44, 45-64
Body Types Obese
Notes for this study:
Supplementation of 800 IU vitamin E (as alpha-tocopherol) daily for 96 weeks in persons with non-alcoholic fatty liver disease (NAFLD) appeared to reduce circulating ALT and liver fat scores in approximately 50% of the group (more than placebo) although liver fibrosis was not affected.

Effects Of Gamma-tocopherol Supplementation On Thrombotic Risk Factors

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 39
Gender Both Genders
Age Range 18-29, 30-44
Body Types Average
Notes for this study:
Supplementation of gamma-tocopherol at 100mg or 200mg daily over a period of five weeks in otherwise healthy subjects noted a small reduction in platelet aggregation at the lower dose only, with other paramters not significantly affected (a mild reduction in LDL and increase in HDL was present at the lower yet not higher dose, despite dose-dependent increases in plasma gamma-tocopherol).

P-selectin (a cell adhesion factor) was decreased in both supplemental groups () with no apparent dose-dependent effects.

Assessment Of The Safety Of Supplementation With Different Amounts Of Vitamin E In Healthy Older Adults

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 88
Gender Both Genders
Age Range 65+
Notes for this study:
Supplementation of vitamin E at three doses (60, 200, and 800 IU) daily for four months failed to significantly modify any measured parameter relative to placebo in a sub-chronic safety testing study.

The Relationship Between Dose Of Vitamin E And Suppression Of Oxidative Stress In Humans

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 35
Gender Both Genders
Age Range 30-44
Notes for this study:
Supplementation of high doses of vitamin E (1,600-3,200IU) daily for 16 weeks in hypercholesterolemic persons was able to reduce plasma F2 isoprostanes, but lower doses were not effective. No dose increased oxidation.

It was noted in a preliminary trial that 16 weeks are required for sufficient antioxidant properties to manifest with shorter periods of time ineffective.